Gyre Therapeutics, Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)
Gyre Therapeutics, Inc. (GYRE) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) of -$5.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes
us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease · last filed 2023-03-30
- Gyre Therapeutics, Inc. sec schedule, 12-09, valuation allowances and reserves, period increase (decrease) for fiscal 2022 was -$5.50M, a 123.81% decline from fiscal 2021.
- Gyre Therapeutics, Inc. sec schedule, 12-09, valuation allowances and reserves, period increase (decrease) for fiscal 2021 was $23.10M, a 234.78% increase from fiscal 2020.
- Gyre Therapeutics, Inc. sec schedule, 12-09, valuation allowances and reserves, period increase (decrease) for fiscal 2020 was $6.90M, a 59.88% decline from fiscal 2019.
- Gyre Therapeutics, Inc. sec schedule, 12-09, valuation allowances and reserves, period increase (decrease) for fiscal 2019 was $17.20M.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) 12 month as first filed |
|---|---|---|
| 2022-12-31 | -$5.50M 10-K · filed 2023-03-30 | |
| 2021-12-31 | $23.10M 10-K · filed 2023-03-30 | -$23.10M 10-K · filed 2022-03-31 |
| 2020-12-31 | $6.90M 10-K · filed 2022-03-31 | -$6.90M 10-K · filed 2021-03-04 |
| 2019-12-31 | $17.20M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |